Proficient mismatch repair, abbreviated pMMR, means a tumor’s DNA repair machinery is functioning as intended, and that designation carries major consequences for treatment decisions, prognosis, and eligibility for immunotherapy. Roughly two-thirds to four-fifths of common solid tumors, including most colorectal and endometrial cancers, fall into this category. The significance is somewhat counterintuitive: having “working” repair sounds like a good thing, but in the world of cancer treatment, pMMR tumors tend to be harder to treat with the immune checkpoint inhibitors that have transformed outcomes for their repair-deficient counterparts. That tension between a healthy-sounding label and a more difficult clinical reality is at the heart of why pMMR status has become one of the most important molecular markers in oncology.
What the Mismatch Repair System Does
Every time a cell divides, its DNA replication machinery copies billions of base pairs. Mistakes happen, and the mismatch repair system is the proofreading crew that catches and fixes those errors before they become permanent mutations. The key players are proteins called MLH1, MSH2, MSH6, and PMS2, which work in pairs to scan newly copied DNA, recognize mismatched bases, and coordinate their removal. When this system is intact and working, the cell maintains what researchers call genomic stability: its DNA stays relatively clean from one division to the next. The phosphorylation of the MSH2 and MSH6 proteins, which form the main mismatch-recognizing complex, is one layer of regulation that keeps the system active and responsive to errors.
When the system breaks down, the result is deficient mismatch repair (dMMR), which leads to a rapid accumulation of mutations, particularly in short repetitive DNA sequences called microsatellites. This condition, known as microsatellite instability, is what makes dMMR tumors look very different from pMMR tumors under the molecular microscope. A pMMR tumor, by contrast, has relatively few of those replication-driven mutations. Its genome is more stable, but that stability creates its own set of clinical challenges.
How pMMR Status Is Determined
Testing has become standard practice in colorectal cancer diagnosis and is expanding into other tumor types. There are two main approaches. The first and most widely used is immunohistochemistry (IHC), where pathologists stain a tissue sample for the four mismatch repair proteins. If all four show normal expression, the tumor is classified as pMMR. The second method uses PCR-based or sequencing-based molecular tests that directly measure microsatellite stability or instability at specific DNA markers.1PubMed Central. Testing for deficient mismatch repair and microsatellite instability: A focused update Current clinical guidelines recommend either IHC or molecular microsatellite instability testing as predictive markers for immunotherapy eligibility.2Pathology and Oncology Research. Microsatellite instability and mismatch repair protein deficiency: equal predictive markers?
These two methods usually agree, but not always, and the discordant cases matter. A study examining heterogeneous expression patterns found that some tumors classified as pMMR by IHC actually tested as microsatellite-unstable when checked with molecular methods. In colorectal cancer specifically, cases with small focal loss of MSH6 expression (fewer than about 15% of tumor cells staining positive) had a high likelihood of being microsatellite-unstable despite an initial pMMR reading. In endometrial cancer, the pattern was different: tumors with broader patchy loss of repair protein staining still turned out to be microsatellite-stable on molecular testing.3PubMed. Heterogeneous expression of mismatch repair proteins and interpretation of immunohistochemical results in colorectal cancer and endometrial cancer The practical takeaway is that a pMMR label from IHC alone is not always the final word, particularly for right-sided colon tumors, where supplemental molecular testing has been shown to catch a meaningful fraction of misclassified cases.4PubMed Central. Certain pMMR colorectal cancer patients should undergo additional MSI-PCR testing to reduce the risk of misdiagnosing MSI-H and Lynch syndrome
The Prognosis Puzzle Depends on Stage
One of the most clinically relevant findings about pMMR is that its prognostic meaning flips depending on how advanced the cancer is. In stage II colon cancer, patients with dMMR tumors tend to do somewhat better than those with pMMR tumors. A study examining this stage-dependent shift found that five-year disease-free survival was higher in the dMMR group than the pMMR group for stage II disease.5PubMed Central. Stage-dependent prognostic shift in mismatch repair-deficient tumors: Assessing patient outcomes in stage II and III colon cancer Data from another cohort put numbers on this directly: in stage II colon cancer, five-year disease-free survival was roughly 98% for dMMR patients compared to about 82% for pMMR patients.6Journal of Clinical Oncology. Prognostic role of mismatch repair status in stage II colon cancer at Ho Chi Minh City Oncology Hospital
In stage III colon cancer, the relationship reverses. The same stage-dependent analysis found that dMMR became a marker of worse disease-free survival, with a hazard ratio over four times higher for recurrence compared to pMMR patients.5PubMed Central. Stage-dependent prognostic shift in mismatch repair-deficient tumors: Assessing patient outcomes in stage II and III colon cancer The interaction between repair status and disease stage was statistically significant, meaning these are not just random fluctuations. For clinicians making treatment decisions, this means that knowing a tumor is pMMR is only half the picture; the stage of the cancer fundamentally changes what that label predicts.
Why pMMR Tumors Resist Immunotherapy
The central challenge of pMMR cancers is their relationship with the immune system. Immune checkpoint inhibitors work by removing molecular “brakes” that prevent T cells from attacking cancer cells. These drugs have been spectacularly successful in dMMR tumors, which are loaded with mutations and therefore produce many abnormal proteins (neoantigens) that the immune system can recognize as foreign. The pMMR tumor microenvironment is typically the opposite: low neoantigen load, poor T-cell infiltration, and dominant immunosuppressive networks.7OncoTargets and Therapy. Mechanisms and Emerging Strategies to Overcome Immunotherapy Resistance in Cold Tumours of Colorectal Cancer
Researchers describe these tumors as immunologically “cold.” The cancer cells simply don’t generate enough abnormal signals to attract a robust immune response, and the surrounding tissue actively suppresses whatever immune cells do show up. This is why single-agent checkpoint inhibitors have historically failed in pMMR colorectal cancer, and why the search for combination strategies to “heat up” these tumors has become one of the most active areas of clinical oncology research.
Endometrial Cancer Changed the Narrative
The first major breakthrough for treating pMMR tumors came in endometrial cancer. The KEYNOTE-775 trial tested the combination of lenvatinib, a drug that targets blood vessel growth and certain signaling pathways, with pembrolizumab, a checkpoint inhibitor. In patients with pMMR advanced endometrial cancer, this combination roughly doubled progression-free survival compared to chemotherapy (about 6.6 months versus 3.8 months) and extended overall survival from roughly 12 months to over 17 months.8PubMed Central. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer Those results established lenvatinib plus pembrolizumab as the standard of care for patients with pMMR recurrent endometrial cancer who had failed prior platinum-based chemotherapy.9PubMed. Evaluation of the combination lenvatinib and pembrolizumab in endometrial cancer; a real world multi-institutional review of practice patterns, efficacy and tolerability
The importance of this result goes beyond endometrial cancer. It demonstrated a principle: pairing a checkpoint inhibitor with a drug that remodels the tumor’s blood supply and microenvironment can create enough immune activity to overcome the “cold” tumor problem, even in pMMR cancers. The combination is not without trade-offs. Lenvatinib brings its own side-effect profile, including high blood pressure, fatigue, and hand-foot skin reactions, and real-world experience has focused on how patients tolerate the regimen outside the controlled setting of a clinical trial.10PubMed. Pembrolizumab plus lenvatinib combination therapy for advanced endometrial carcinoma Still, for a population of patients who previously had very limited options after chemotherapy failed, the improvement was meaningful.
The Colorectal Cancer Frontier
Cracking the pMMR problem in colorectal cancer has proven harder. A phase I/Ib trial combining regorafenib, another blood-vessel-targeting drug, with nivolumab in patients with metastatic pMMR colorectal cancer found the combination was tolerable but showed limited anticancer activity.11European Journal of Cancer. A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer A larger phase II study of the same combination reported an overall response rate of only 7% across all patients, though results were notably better in patients without liver metastases, where the response rate climbed to about 22%.12The Lancet Regional Health / eClinicalMedicine. Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer
That difference based on metastasis location hints at something important about pMMR tumors: they are not one monolithic entity. The liver is a notoriously immunosuppressive organ, and tumors that have spread there may be even more resistant to immune-based approaches than pMMR tumors growing elsewhere. This site-specific variability is shaping how trials are designed, with some studies now specifically enrolling patients without liver involvement to test combinations that might work in a more favorable immune context.
Co-occurring genetic mutations also matter. About 40% of colorectal cancers carry mutations in the KRAS gene, and about 10% have BRAF mutations. Both of these drive constant activation of a growth-promoting signaling cascade that makes cells resistant to certain targeted therapies.13PubMed Central. Targeting BRAF and RAS in Colorectal Cancer In the pMMR population, these mutations further complicate the treatment picture because they layer additional drug resistance on top of the already limited immune responsiveness.
A Subset of pMMR Tumors That Do Respond
Not all pMMR tumors are equally cold. The NICHE trial investigated neoadjuvant immunotherapy, meaning checkpoint inhibitors given before surgery, in patients with early-stage pMMR colon cancer. Of 31 patients who received nivolumab plus ipilimumab before their operations, about a quarter showed a meaningful pathological response, including three patients who had complete pathological responses with no residual viable tumor found at all.14PubMed Central. Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers
Deeper molecular analysis of the responders versus non-responders revealed a pattern. The pMMR tumors that responded tended to have higher chromosomal instability, TP53 mutations, and gene expression signatures associated with active cell proliferation. They also had more immune cells present within the tumor before treatment started, particularly CD8-positive T cells.15PubMed Central. A subset of MMR-proficient colon cancers responds to neoadjuvant immunotherapy This is a critical finding because it suggests that within the large, seemingly uniform pMMR population, there is a biologically distinct subgroup whose tumors are more immunogenic and potentially treatable with immunotherapy. The challenge now is figuring out how to reliably identify these patients before treatment begins, rather than discovering it after surgery.
The chromosomal instability pathway itself is the dominant route through which most colorectal cancers develop, characterized by widespread imbalances in chromosome number and the accumulation of mutations in classic tumor-suppressor genes and oncogenes.16PubMed Central. The chromosomal instability pathway in colon cancer So while pMMR tumors lack the microsatellite-driven mutation burden of dMMR cancers, some of them generate their own form of genomic chaos through chromosomal scrambling, which may produce enough abnormal signals to provoke an immune response after all.
Experimental Strategies to Overcome Immune Resistance
Because most pMMR tumors do not respond to existing immunotherapies, researchers are pursuing several creative strategies to change the equation. One approach involves personalized neoantigen vaccines designed to teach a patient’s immune system to recognize the specific abnormal proteins produced by their individual tumor. A preclinical study developed such a vaccine targeting microsatellite-stable colorectal cancer cells and combined it with regorafenib, showing that the combination increased infiltration of immune T cells into the tumor and reprogrammed the surrounding microenvironment.17PubMed Central. Personalized Neoantigen Vaccine plus Regorafenib Increases Rgs2⁺CD8⁺ T Cells Infiltration and Reprograms the Tumor Microenvironment in Microsatellite Stable Colorectal Cancer Liver Metastases Early-phase clinical work with a similar personalized vaccine platform in patients with microsatellite-stable metastatic colorectal cancer is already underway, testing whether neoantigen vaccination combined with a checkpoint inhibitor can shift the cold tumor microenvironment toward one that supports an immune attack.18Cancer Research. Personalized neoantigen vaccine with or without pembrolizumab in patients with microsatellite-stable metastatic colorectal cancer
A more radical strategy goes directly at the mismatch repair system itself. Mouse experiments have shown that deliberately knocking out mismatch repair genes in pMMR tumor cells made those tumors dramatically more immunogenic. When two repair genes were simultaneously disabled in colorectal, breast, and melanoma cell lines, the resulting tumors triggered rapid immune-mediated growth inhibition or outright rejection. Tumors that survived the initial immune assault could then be eliminated by adding a checkpoint inhibitor. Intriguingly, the immune response was not driven by the traditional mechanism of T cells recognizing tumor-specific antigens, but instead appeared to involve an innate immune receptor that senses the genotoxic stress of unrepaired DNA damage. The protection even extended to unrelated tumors that had not been genetically modified.19Cancer Research. Disrupting mismatch repair makes mismatch repair-proficient tumors immunogenic and induces CD8 T cell-dependent, but T cell receptor-independent, immune control of heterologous tumors in mice This is still early-stage preclinical work, and deliberately breaking a DNA repair system in human patients raises obvious safety questions. But it offers a proof of concept that the immunological silence of pMMR tumors is not permanent and can be disrupted.
Reducing Testing Costs Without Losing Accuracy
As molecular testing expands beyond colorectal cancer into routine workup for endometrial cancer and potentially other tumor types, the cost of testing becomes a practical concern. The standard four-protein IHC panel checks for MLH1, MSH2, MSH6, and PMS2. However, the way these proteins function in pairs means you can sometimes get the same diagnostic information from fewer tests. A cost-effectiveness analysis in endometrial cancer found that testing only two proteins, PMS2 and MSH6, achieved a sensitivity of over 99.8% for detecting mismatch repair deficiency. Using this two-protein screen with reflex methylation testing when needed resulted in substantial cost savings compared to the full four-protein panel, without meaningfully sacrificing diagnostic accuracy.20Journal of Clinical Oncology. Cost-effectiveness of a two-protein panel PMS2/MSH6 for detecting mismatch repair deficiency in endometrial cancer: A single institution study
This matters most in settings where healthcare resources are constrained. If testing is expensive or difficult to access, some patients may not get tested at all, which means missed Lynch syndrome diagnoses and missed opportunities for targeted treatment. Streamlined testing approaches that maintain accuracy while reducing cost could make universal screening more practical across a wider range of institutions.
The Ancient Origins of Mismatch Repair
The mismatch repair system is not a recent evolutionary invention. Phylogenetic analysis of the core repair genes MutS and MutL, from which human MSH and MLH proteins descend, has traced their origins deep into the bacterial world. The system has been shaped by multiple horizontal gene transfer events across different domains of life and has diversified into several subfamilies, including at least three beyond the two that were originally well-characterized.21PubMed Central. The origins and early evolution of DNA mismatch repair genes–multiple horizontal gene transfers and co-evolution The deep conservation of this system across bacteria, archaea, and eukaryotes underscores how fundamental error correction is to life that relies on DNA replication. When cancer disrupts it, or when it remains intact while cancer finds other routes to grow, the consequences reflect billions of years of evolutionary investment in genomic fidelity working for or against the patient in ways that oncologists are still learning to navigate.